通肺饮吸入法治疗痰瘀互结型非小细胞肺癌的临床研究

目的:观察通肺饮超声雾化吸入联合化疗对非小细胞肺癌的临床疗效,并初步探讨其作用机理。方法:采用随机法将90例非小细胞肺癌痰瘀互结型患者分为治疗组(化疗加通肺饮雾化)30例、对照组(化疗加通肺饮口服)30例和空白组(单纯化疗)30例,比较3组临床完成情况、近期客观疗效、治疗前后临床症状、生活质量卡氏评分、体重、免疫功能(NK细胞)的变化和毒副反应情况。结果:治疗组和对照组可较好改善部分临床症状,稳定并增加体重,提高患者生存质量,保护机体免疫功能,减轻化疗毒副反应;但在减小和稳定病灶方面与单纯化疗组相比无显著性差异(P>0.05);治疗组和对照组相比,雾化吸入法通过呼吸道给药,可直接作用于病灶,易于被患者接受(P<0.05)。结论:肺饮超声雾化吸入对非小细胞肺癌有较好的临床效果。

Clinical Research on Patients with Non-Small Lung Cancer Interfered by Tongfei Decoction Inhalation Therapy

Objective:To observe the clinical effect of Tongfei Decoction by ultrasonic atomizing inhalation combined with chemotherapy and to explore its mechanism.Methods:90 patients with Non-small Lung Cancer with the syndrome of phlegm and blood-stasis type were randomly divided into treatment group 30 cases(chemotherapy combined with Tongfei Decoction by atomizing inhalation),control group 30 cases(chemotherapy combined with Tongfei Decoction by oral),and blank group 30 cases(chemotherapy alone).The clinical completion,recent objective effect,clinical symptoms before and after treatment,Card′s score of life quality,weight,immune function(NK cells)and toxicity among three groups were compared.Results:Part of the clinical symptoms can be improved,weight can be stabilized and increased,life quality of patients can be improved,immune function can be protected,chemotherapy toxicity can be reduced in treatment and control groups.There was no significant difference in reducing and stabilizing lesion area compared with chemotherapy alone(P>0.05);compared with control group,atomizing inhalation in treatment group through respiratory tract was directly on the lesion,so it can be easily accepted by patients(P<0.05).Conclusion:Tongfei Decoction by atomizing inhalation has better clinical effects on non-small lung cancer.